Form D · Biotechnology
Axon Therapeutics, Inc.
San Diego, CA · CIK 0001943790
Offering snapshot reported Aug 25, 2022 · SEC filing
- Reported sold
- $5M Offering amount: $5M
- Investors reported
- 2 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Aug 10, 2022 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Aug 25, 2022 | Initial | $5,000,000 | No comparison | 2 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-457035
Source: Form D, filed Aug 25, 2022. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| David C Dodick | Director |
| Frank Porreca | Director |
| Pierre Riviere | Director, Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
3993 Via Cangrejo
San Diego, CA, 92130
San Diego, CA, 92130